REFERENCES
D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisin, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert: The P450 superfamily: Update on new sequences, gene mapping, accession numbers, earily trival names of enzymes, and nomenclature. DNA Cell Biol. 12:1–51 (1993).
S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Tox. 22:1–21 (1992).
P. K. Honig, D. C. Wortham, K. J. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena: Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–1518 (1993).
P. K. Honig, R. L. Woosley, K. Zamani, D. P. Conner, and L. R. Cantilena: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52:231–238 (1992).
T. A. van der Hoeven and M. J. Coon: Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249:6302–6310 (1974).
T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molec. Pharmacol. 36:89–96 (1989).
I. H. Segel: Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme systems, John Wiley and Sons, New York, 1975.
M. P. Gascon and P. Dayer: In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J. Clin. Pharmacol. 41:573–578 (1991).
G. T. Tucker: The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Internat. J. Clin. Pharmacol. Ther. Toxicol. 30:550–553 (1992).
Physicians Desk Reference. 47th edition. Medical Economics Data, a division of Medical Economics Company Inc., Montvale, NJ, 1993.
C. H. Kleinbloesem, P. van Brummelen, and D. D. Breimer: Nifedipine, relationship between pharmacokinetics and pharmacodynamics. Clin. Pharmacokinetics 12:12–29 (1987).
M. Murray: Mechanisms of the inhibition of cytochrome P450-mediated drug oxidation by therapeutic agents. Drug Metab. Rev. 18:55–81 (1987).
A. F. Shinn: Clinical relevance of cimetidine drug interactions. Drug Safety 7:245–267 (1992).
C. C. Peck, R. Temple and J. M. Collins. Understanding consequences of concurrent therapies. JAMA 269:1550–1552 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wrighton, S.A., Ring, B.J. Inhibition of Human CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and Nizatidine. Pharm Res 11, 921–924 (1994). https://doi.org/10.1023/A:1018906614320
Issue Date:
DOI: https://doi.org/10.1023/A:1018906614320